NCT06632873View on ClinicalTrials.gov

177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

February 20, 2025

Conditions
SSTR2 and Integrin αVβ3 Positive Tumors
Interventions
DRUG

177Lu-TATE-RGD

accepted intravenous injection of 177Lu-TATE-RGD

Trial Locations (1)

100730

RECRUITING

Chinese Academy of Medical Science & Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER